Welcome to our dedicated page for SILICON LABORATORIES SEC filings (Ticker: SLAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Silicon Laboratories Inc. filings document an operating semiconductor company focused on low-power wireless connectivity, embedded SoCs and security technology for edge devices. Its 8-K reports cover operating results, financial condition, non-GAAP measures, material-event disclosures, capital-structure items, material agreements and solicitation materials tied to shareholder matters.
Proxy and annual meeting filings disclose board elections, auditor ratification, executive compensation votes and amendments to the 2009 Stock Incentive Plan. The filings also identify the company’s Nasdaq-listed common stock and provide formal records of governance actions, equity-plan matters and stockholder voting outcomes.
Form 144 notice by an insider proposing sale of Silicon Laboratories Inc. common stock. The filer plans to sell 8,000 shares through Fidelity Brokerage Services with an aggregate market value of $1,161,818.01 on or about 08/22/2025. The shares were acquired via an option granted on 01/28/2016 and payment on sale is listed as cash. The issuer's outstanding shares are reported as 32,815,310. A recent sale by Brandon Tolany of 2,270 shares on 08/19/2025 generated $301,206.53. The filer certifies no undisclosed material adverse information.
Tolany Brandon, Sr VP WW Sales & Marketing at Silicon Laboratories Inc. (SLAB), reported transactions on 08/19/2025 involving exercises of stock options and an open-market sale. The filing shows exercises of two non-qualified stock options at an exercise price of $43.82 each, resulting in the acquisition of 35 and 2,235 shares. The filing also reports a sale of 2,270 shares at $132.69. After these transactions, the reported beneficial ownership totals are shown as 62,328 shares (final reported balance). The option grants cited have original grant dates of 01/28/2019 and 01/28/2020 with expiration 01/28/2026.
The filing is a Form 144 notice from an individual related to Silicon Laboratories Inc. It reports a proposed sale of 2,270 shares of Common stock through Fidelity Brokerage Services on the NASDAQ, with an aggregate market value of $301,206.53 and 32,815,310 shares outstanding for the class. The shares were acquired via an option granted on 01/28/2016 and are indicated as acquired on 08/19/2025; payment is listed as cash. The filer reports no other sales in the past three months and includes the standard representation that they are not aware of undisclosed material adverse information about the issuer.
Capital Research Global Investors disclosed beneficial ownership of 1,206,937 shares of Silicon Laboratories Inc. common stock, equal to 3.7% of the 32,571,850 shares the filer believes are outstanding. The filing identifies CRGI as a division of Capital Research and Management Company and states that the investment management entities acting under the CRGI name are deemed the beneficial owner of these shares.
The statement indicates CRGI has sole voting and sole dispositive power over the reported shares and certifies the securities were acquired and are held in the ordinary course of business, not to change or influence control of the issuer.